Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval, the field has ...

It is a running gag around here that whenever a project posts, someone will inevitably point out that it could have been done ...

After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...

It’s always nice to simulate a project before soldering a board together. Tools like QUCS run locally and work quite well for ...